Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL853922 | 0.98 | KMT2A (0.51) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL2687539 | 0.88 | MEN1 (0.46) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL25306284 | 0.88 | MEN1 (0.46) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL14275538 | 0.88 | MEN1 (0.46) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| Hydrochloric Acid SCHEMBL31727051 | 0.86 | MEN1 (0.45) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL6586735 | 0.85 | MAPT (0.44) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL616596 | 0.82 | KMT2A (0.56) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL3807935 | 0.81 | GNAI3 (0.42) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL22549806 | 0.80 | GNAI3 (0.39) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL10274875 | 0.80 | MEN1 (0.55) | KMT2AMEN1SMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| EP-3027604-B1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-02-20 | — | — | EP | disclosed |
| US-20180092924-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-04-05 | — | — | US | disclosed |
| US-9855271-B2 | Quinazolinones as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-02 | — | — | US | disclosed |
| US-20160193218-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2016-07-07 | — | — | US | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| EP-2433943-A1 | Thienopyrazole derivatives having PDE7 inhibitory activity | Daiichi Sankyo Company, Limited (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | KMT2A 3266/4885MEN1 3519/4885SMN1; SMN2 4191/4885 |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | KMT2A 3266/4885MEN1 3519/4885SMN1; SMN2 4191/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | KMT2A 3266/4885MEN1 3519/4885SMN1; SMN2 4191/4885 |
| US-20180092924-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | KMT2A 825/4885MEN1 3523/4885SMN1; SMN2 4266/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | KMT2A 933/4885MEN1 1254/4885SMN1; SMN2 4097/4885 |
| US-20160193218-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | KMT2A 825/4885MEN1 3523/4885SMN1; SMN2 4266/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | KMT2A 2825/4885MEN1 1398/4885SMN1; SMN2 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.